Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04659616
Title Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors OHSU Knight Cancer Institute

acute myeloid leukemia


Cytarabine + Pemigatinib

Cytarabine + Daunorubicin + Pemigatinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST